Current Dermatology Reports最新文献_第4页

Emerging Fungal Infections and Cutaneous Manifestations in Immunosuppressed Patients 免疫抑制患者的新发真菌感染和皮肤表现

IF 1.6

Current Dermatology Reports Pub Date : 2023-04-05 DOI: 10.1007/s13671-023-00386-9

J. Varghese, S. Guhan, Lida Zheng

引用次数: 0

Compression Therapy in Dermatology 皮肤科的压迫疗法

IF 1.6

Current Dermatology Reports Pub Date : 2023-03-31 DOI: 10.1007/s13671-023-00388-7

M. Romanelli, Flavia Manzo Margiotta, Alessandra Michelucci, G. Granieri, A. Janowska, V. Dini

引用次数: 1

Lessons Learned from Anatomic Susceptibility in Vitiligo Patients: A Systematic Review 从白癜风患者的解剖学易感性中吸取的经验教训：一项系统综述

IF 1.6

Current Dermatology Reports Pub Date : 2023-03-17 DOI: 10.1007/s13671-023-00384-x

Parsa Abdi, H. Maibach, Christopher Farkouh, R. Law, Christian Awad

引用次数: 1

Hypersensitivity to Implanted Metal Devices 对植入金属装置过敏

IF 1.6

Current Dermatology Reports Pub Date : 2023-01-31 DOI: 10.1007/s13671-023-00381-0

B. Schwartz, D. Pithadia, Jennifer K. Chen

引用次数: 0

Challenges in Textile Contact Dermatitis 纺织品接触性皮炎面临的挑战

IF 1.6

Current Dermatology Reports Pub Date : 2023-01-25 DOI: 10.1007/s13671-023-00383-y

S. Nedorost

引用次数: 0

Patient Satisfaction in Teledermatology: an Updated Review. 远程皮肤科患者满意度:最新综述。

IF 1.6

Current Dermatology Reports Pub Date : 2023-01-01 DOI: 10.1007/s13671-023-00382-z

Sueheidi Santiago, Jun Lu

{"title":"Patient Satisfaction in Teledermatology: an Updated Review.","authors":"Sueheidi Santiago, Jun Lu","doi":"10.1007/s13671-023-00382-z","DOIUrl":"https://doi.org/10.1007/s13671-023-00382-z","url":null,"abstract":"Purpose of review: Teledermatology continues to gain popularity across the world. It is crucial that dermatologists understand patient experience and satisfaction to effectively incorporate this practice into patient care. This article provides an updated review of recent findings on patient satisfaction in teledermatology.Recent findings: Over the last 2 years, there has been an increase in studies on the patient experience of live-video teledermatology, while previous studies largely focused on store-and-forward teledermatology. This reflects the expansion of live-video teledermatology since the COVID-19 pandemic. Patients are generally very satisfied with both store-and-forward and live-video teledermatology, valuing its accessibility, quality of care, and patient-provider relationship. Decreased patient satisfaction is linked to technical difficulties, privacy concerns, lack of procedure availability, and thorough physical exams. However, teledermatology experiences are not equal across demographic groups. Access to technical support, digital literacy, age, social economic status, and type of dermatological conditions have all been found to affect patient experience.Summary: Studies show high levels of patient satisfaction in teledermatology but limitations exist. Future efforts to improve teledermatology experiences will require reducing barriers among demographics, improving patient education, investment in technology, and collaboration among all parties involved.","PeriodicalId":10838,"journal":{"name":"Current Dermatology Reports","volume":"12 1","pages":"23-26"},"PeriodicalIF":1.6,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9880362/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9260740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 5

The Impact of Immune-Modulating Treatments for Dermatological Diseases on the Risk of Infection with SARS-CoV-2 and Outcomes Associated with COVID-19 Illness. 皮肤病免疫调节治疗对感染SARS-CoV-2的风险和与新冠肺炎疾病相关的结果的影响。

IF 2.4

Current Dermatology Reports Pub Date : 2023-01-01 Epub Date: 2023-04-03 DOI: 10.1007/s13671-023-00385-w

Nicole Maynard, April W Armstrong

{"title":"The Impact of Immune-Modulating Treatments for Dermatological Diseases on the Risk of Infection with SARS-CoV-2 and Outcomes Associated with COVID-19 Illness.","authors":"Nicole Maynard, April W Armstrong","doi":"10.1007/s13671-023-00385-w","DOIUrl":"10.1007/s13671-023-00385-w","url":null,"abstract":"Purpose of review: Immune-modulating treatments are used in dermatology for a variety of conditions. The authors aim to review the data regarding the safety of these treatments during the COVID-19 pandemic, namely the risk of infection with SARS-CoV-2 and the outcomes associated with COVID-19-related illness.Recent findings: Several large-scale studies found no increased risk of COVID-19 infection for patients on TNF-α inhibitors, IL-17 inhibitors, IL-12/23 inhibitors, IL-23 inhibitors, dupilumab, and methotrexate. They also found that these patients did not have worse outcomes when infected with COVID-19. The data regarding JAK inhibitors, rituximab, prednisone, cyclosporine, mycophenolate mofetil, and azathioprine are more mixed.Summary: Based on current research and guidelines from the American Academy of Dermatology and the National Psoriasis Foundation, dermatology patients on immune-modulating therapies can continue treatment during the COVID-19 pandemic when they are not infected with SARS-CoV-2. For patients who have COVID-19, guidelines encourage individualized assessment of the benefits and risks of continuing or temporarily withholding treatment.","PeriodicalId":10838,"journal":{"name":"Current Dermatology Reports","volume":"12 2","pages":"45-55"},"PeriodicalIF":2.4,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10068706/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9992427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pityriasis Lichenoides Following SARS-CoV-2 Infection/Vaccination. SARS-CoV-2感染/接种后的地衣样糠疹。

IF 1.6

Current Dermatology Reports Pub Date : 2023-01-01 DOI: 10.1007/s13671-023-00380-1

Aileen M Feschuk, Maxwell Green, Nadia Kashetsky, Howard I Maibach

{"title":"Pityriasis Lichenoides Following SARS-CoV-2 Infection/Vaccination.","authors":"Aileen M Feschuk, Maxwell Green, Nadia Kashetsky, Howard I Maibach","doi":"10.1007/s13671-023-00380-1","DOIUrl":"https://doi.org/10.1007/s13671-023-00380-1","url":null,"abstract":"Purpose of review: Pityriasis lichenoides (PL) is a spectrum of dermatological conditions involving polymorphous lesions. Natural history of the condition ranges from acute to chronic. Cases of PL following SARS-CoV-2 infection/vaccination have been reported, but not yet comprehensively reviewed. Hence, the objective of this article is to review and summarize cases of PL following SARS-CoV-2 infection/vaccination in order to guide clinicians in its diagnosis and management.Recent findings: PubMed, Embase, and Web of Science were searched for relevant articles. Thirteen articles, consisting of 14 cases of PL following SARS-CoV-2 infection/vaccination, were identified. Males represented 64.3% of cases, and the average age of those affected was 41.4 years. The majority of cases (N = 9, 64.3%) were following SARS-CoV-2 vaccination, the most commonly implicated being Pfizer-BioNTech (n = 8/10, 80%), while four (28.6) followed infection. The overall latency period ranged from 5 days to 1 month. Treatments varied greatly. However, at the time of follow-up, 12/14 patients (85.7%) had either marked improvement or complete resolution of lesions.Summary: This review cannot determine causality. However, a temporal association was observed with the case reports, and one case of PL followed SARS-CoV-2 infection and recurred with subsequent vaccination, suggesting an association. Nevertheless, risk of developing PL following SARS-CoV-2 infection/vaccination is likely extremely low. There is also the possibility these cases are purely coincidental. Still, clinicians should be aware of this possible etiology when diagnosing a new or exacerbated case of PL. Finally, given that the majority of patients had marked improvement or complete resolution of lesions at the time of follow-up, clinicians should provide reassurance to their affected patients.","PeriodicalId":10838,"journal":{"name":"Current Dermatology Reports","volume":"12 1","pages":"27-32"},"PeriodicalIF":1.6,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9844164/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10279694","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Epidemiology of Hidradenitis Suppurativa: Current Status 化脓性Hidradenitis的流行病学现状

IF 1.6

Current Dermatology Reports Pub Date : 2022-10-11 DOI: 10.1007/s13671-022-00372-7

Diana Díaz, Alejandra Rivera, Valentina Otero, L. Rueda

引用次数: 1

Tattoo-Related Allergic Contact Dermatitis 纹身相关过敏性接触性皮炎

IF 1.6

Current Dermatology Reports Pub Date : 2022-10-06 DOI: 10.1007/s13671-022-00371-8

K. Daftary, W. Liszewski

引用次数: 0